Neurocrine Biosciences, Inc. NBIX
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 17.07% | 17.74% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 17.07% | 17.74% | |||
| Cost of Revenue | 7.33% | 11.84% | |||
| Gross Profit | 22.59% | 21.37% | |||
| SG&A Expenses | -6.92% | 20.28% | |||
| Depreciation & Amortization | 113.41% | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.35% | 18.73% | |||
| Operating Income | 68.70% | 14.41% | |||
| Income Before Tax | 74.91% | -34.28% | |||
| Income Tax Expenses | 333.71% | -63.60% | |||
| Earnings from Continuing Operations | 43.01% | -27.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 43.01% | -27.03% | |||
| EBIT | 68.70% | 14.41% | |||
| EBITDA | 69.61% | 22.92% | |||
| EPS Basic | 42.16% | -27.40% | |||
| Normalized Basic EPS | 62.64% | 3.31% | |||
| EPS Diluted | 41.01% | -27.23% | |||
| Normalized Diluted EPS | 62.05% | 3.04% | |||
| Average Basic Shares Outstanding | 0.59% | 0.50% | |||
| Average Diluted Shares Outstanding | 0.96% | 0.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||